Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: A meta-analysis

被引:24
作者
Xie, HG
Xu, ZH
Luo, XA
Huang, SL
Zeng, FD
Zhou, HH
机构
[1] HUNAN MED UNIV,PHARMACOGENET RES INST,CHANGSHA 410078,PEOPLES R CHINA
[2] TONGJI MED UNIV,DEPT CLIN PHARMACOL,WUHAN 430030,PEOPLES R CHINA
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
debrisoquine; metoprolol; codeine; mephenytoin; CYP2C19; CYP2D6; phenotyping; Chinese; meta-analysis;
D O I
10.1097/00008571-199606000-00005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Chinese data on the polymorphic metabolism of debrisoquine, metoprolol, codeine and mephenytoin were collected and reanalysed using a meta-analysis method, There were no significant differences in the incidences of poor metabolizer (PM) between the separate series of debrisoquine, metoprolol and codeine, which are the three probe drugs reflecting the same enzyme polymorphism, PMs were detected at low frequencies for debrisoquine (1.20%; 95% confidence interval, CI: 0.67-1.98%), metoprolol (0.72%; CI: 0.29-1.49%) and codeine (0.48%, CI: 0.01-2.68%), The overall estimate of PM was 0.95% (CI: 0.60-1.42%) based on the 2427 determinations of all three probe drugs, The overall mean of PM of mephenytoin was 14.32% (12.26-16.38%) in the 1117 subjects. In summary, the present meta-analysis determined the accurate incidences of the genetic deficiency of S-mephenytoin 4'-hydrosylase (cytochrome P450 2C19) and debrisoquine hydroxylase (cytochrome P450 2D6) in Chinese populations.
引用
收藏
页码:235 / 238
页数:4
相关论文
共 27 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209
[3]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[4]   METABOLIC POLYMORPHISMS [J].
DALY, AK ;
CHOLERTON, S ;
GREGORY, W ;
IDLE, JR .
PHARMACOLOGY & THERAPEUTICS, 1993, 57 (2-3) :129-160
[5]   GENETIC-ANALYSIS OF THE S-MEPHENYTOIN POLYMORPHISM IN A CHINESE POPULATION [J].
DEMORAIS, SMF ;
GOLDSTEIN, JA ;
XIE, HG ;
HUANG, SL ;
LU, YQ ;
XIA, H ;
XIAO, ZS ;
ILE, N ;
ZHOU, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :404-411
[6]   METAANALYSIS - STATE-OF-THE-SCIENCE [J].
DICKERSIN, K ;
BERLIN, JA .
EPIDEMIOLOGIC REVIEWS, 1992, 14 :154-176
[7]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[8]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[9]   METOPROLOL AND MEPHENYTOIN OXIDATION POLYMORPHISMS IN FAR EASTERN ORIENTAL SUBJECTS - JAPANESE VERSUS MAINLAND CHINESE [J].
HORAI, Y ;
NAKANO, M ;
ISHIZAKI, T ;
ISHIKAWA, K ;
ZHOU, HH ;
ZHOU, BJ ;
LIAO, CL ;
ZHANG, LM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) :198-207
[10]   DEBRISOQUINE HYDROXYLATION CAPACITY - PROBLEMS OF ASSESSMENT IN 2 POPULATIONS [J].
INABA, T ;
OTTON, SV ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) :218-223